cGAS–STING activation correlates with improved survival and enhanced checkpoint blockade response in cancer

Photo by Bernd 📷 Dittrich / Unsplash

Frontiers in Medicine Published June 3, 2026 Medically reviewed June 3, 2026 Study authors: Faizah Alabi, Sikiru O. Imodoye, Kamoru A. Adedokun, Mohamed A. Eltokhy, Marina Curcic, Ebenezer Oko… DOI ↗ By Dr. Julia Lee, PhD · Oncology, Genomics & Drug Development

Key Takeaway

Consider that cGAS–STING activation may enhance anti-tumor immunity but excessive activation can cause toxicity.

This is a narrative review that synthesizes preclinical and clinical evidence on cGAS–STING pathway activation in solid tumors and hematologic malignancies. The authors report that heightened cGAS–STING activity correlates with improved survival and enhanced responsiveness to immune checkpoint blockade. Pharmacologic or genetic activation of the pathway suppresses tumor growth, promotes dendritic cell maturation, increases effector immune infiltration, and synergizes with PD-1/PD-L1 inhibition. The review also notes that excessive, systemic, or chronic STING activation can drive immune exhaustion, tolerogenic myeloid reprogramming, and treatment-limiting toxicity. Key limitations acknowledged by the authors include that the spectrum of tumors that derive the greatest therapeutic benefit from STING activation remains incompletely defined, and the mechanisms underlying pathway silencing or non-responsiveness remain incompletely defined. The authors emphasize that much of the evidence is preclinical or from a subset of tumor types, and clinical translation requires further validation.

Study Details

Study typeSystematic review

EvidenceLevel 1

PublishedJun 2026

View Original Abstract ↓

Despite major advances in T cell-directed cancer immunotherapy, many patients fail to achieve durable responses, underscoring the need for approaches that mobilize additional arms of the immune system. The cyclic GMP-AMP synthase–stimulator of interferon genes (cGAS–STING) pathway has emerged as a central cytosolic DNA sensor that initiates robust type I interferon signaling and bridges innate and adaptive antitumor immunity. Clinically, heightened cGAS–STING activity correlates with improved survival and enhanced responsiveness to immune checkpoint blockade in subset of tumor types. Preclinical studies have further demonstrated that the pharmacologic or genetic activation of cGAS–STING suppresses tumor growth, promotes dendritic cell maturation, increases effector immune infiltration, and synergizes with PD-1/PD-L1 inhibition. However, the spectrum of tumors that derive the greatest therapeutic benefit from STING activation and the mechanisms underlying pathway silencing or non-responsiveness remain incompletely defined. In this review, we integrate mechanistic, preclinical, and clinical evidence across solid tumors and hematologic malignancies to delineate the roles of cGAS–STING as both a prognostic biomarker and a therapeutic target. Our synthesis highlights the context-dependent nature of cGAS–STING signaling, with therapeutic outcomes shaped by STING pathway integrity, tumor mutational burden, cytosolic DNA load, and the immunologic composition of the tumor microenvironment. Importantly, we examine emerging evidence that excessive, systemic, or chronic STING activation can drive immune exhaustion, tolerogenic myeloid reprogramming, and treatment-limiting toxicity, which are factors likely to contribute to efficacy limitations of the first-generation STING agonists. We further discuss how rational combination strategies, optimized delivery platforms, and the kinetic control of STING activation may overcome these barriers. Collectively, this synthesis provides a conceptual framework to guide the development of next-generation immunotherapies that leverage cGAS–STING signaling while avoiding the immunosuppressive consequences of dysregulated innate immune activation.